TG Therapeutics (TGTX) Misses Q1 EPS by 3c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TG Therapeutics (TGTX) PT Raised to $40 at Ladenburg Thalmann
May 2, 2024 6:34 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on TG Therapeutics (NASDAQ: TGTX) to $40.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "Strong BRIUMVI 1Q24 revenues with >25% Q/Q growth; TGTX increased BRIUMVI 2024 revenue guidance to $270-$290 million from $220-$260 million. TG... More
